Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Apr 10  •  04:00PM ET
16.49
Dollar change
+0.01
Percentage change
0.06
%
Index
-
P/E
-
EPS (ttm)
-1.02
Insider Own
89.29%
Shs Outstand
354.21M
Perf Week
0.00%
Market Cap
5.84B
Forward P/E
15.44
EPS next Y
1.07
Insider Trans
0.02%
Shs Float
37.94M
Perf Month
-5.77%
Enterprise Value
10.76B
PEG
0.39
EPS next Q
0.05
Inst Own
10.56%
Perf Quarter
-4.68%
Income
-360.00M
P/S
1.15
EPS this Y
52.76%
Inst Trans
-0.83%
Perf Half Y
12.10%
Sales
5.10B
P/B
0.91
EPS next Y
37.05%
ROA
-2.62%
Perf YTD
-3.45%
Book/sh
18.20
P/C
14.72
EPS next 5Y
39.78%
ROE
-5.57%
52W High
18.92 -12.82%
Perf Year
45.67%
Cash/sh
1.12
P/FCF
-
EPS past 3/5Y
- -
ROIC
-3.10%
52W Low
10.45 57.80%
Perf 3Y
-1.14%
Dividend Est.
-
EV/EBITDA
17.67
Sales past 3/5Y
10.62% 8.38%
Gross Margin
54.75%
Volatility
2.54% 3.17%
Perf 5Y
-
Dividend TTM
-
EV/Sales
2.11
EPS Y/Y TTM
-12.96%
Oper. Margin
3.69%
ATR (14)
0.56
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
1.04
Sales Y/Y TTM
6.47%
Profit Margin
-7.06%
RSI (14)
50.48
Dividend Gr. 3/5Y
- -
Current Ratio
1.55
EPS Q/Q
-1825.88%
SMA20
2.35%
Beta
0.66
Payout
-
Debt/Eq
0.81
Sales Q/Q
9.77%
SMA50
-2.30%
Rel Volume
0.82
Prev Close
16.48
Employees
13000
LT Debt/Eq
0.80
SMA200
5.06%
Avg Volume
415.27K
Price
16.49
IPO
May 06, 2022
Option/Short
Yes / Yes
Trades
Volume
340,480
Change
0.06%
Date Action Analyst Rating Change Price Target Change
Jan-05-26Downgrade Evercore ISI Outperform → In-line $18
Dec-11-25Upgrade Citigroup Neutral → Buy $20
Dec-02-25Upgrade Morgan Stanley Equal-Weight → Overweight $21
Oct-01-25Initiated Goldman Neutral $16
May-02-25Reiterated H.C. Wainwright Buy $20 → $15
Mar-28-25Downgrade Wells Fargo Overweight → Equal Weight $24 → $15
Dec-11-24Downgrade Citigroup Buy → Neutral $24 → $22
Dec-02-24Downgrade Morgan Stanley Overweight → Equal-Weight $19
Oct-15-24Upgrade Evercore ISI In-line → Outperform $19 → $25
Jul-10-24Initiated Raymond James Outperform $19
Apr-08-26 07:00AM
Apr-07-26 07:00AM
Apr-06-26 07:00AM
Mar-30-26 07:15AM
Mar-23-26 07:00AM
06:00AM Loading…
Mar-11-26 06:00AM
Mar-09-26 07:15AM
Feb-27-26 12:57PM
05:14AM
Feb-25-26 12:36AM
Feb-24-26 07:00AM
Feb-19-26 12:00PM
12:31AM
Feb-18-26 10:11PM
04:31PM
02:58PM Loading…
02:58PM
02:23PM
02:00PM
01:25PM
01:25PM
09:36AM
09:30AM
08:10AM
07:37AM
07:19AM
06:58AM
Feb-16-26 10:07PM
09:15AM
Feb-12-26 08:50AM
Feb-11-26 09:30AM
11:02PM Loading…
Feb-09-26 11:02PM
11:40AM
Jan-29-26 11:34PM
Jan-23-26 11:40AM
Jan-20-26 07:15AM
Jan-05-26 07:00AM
Jan-02-26 04:30PM
Dec-23-25 07:30AM
Dec-17-25 04:30PM
Dec-12-25 04:48PM
Dec-11-25 11:41AM
Dec-04-25 10:09PM
Dec-02-25 11:10AM
Nov-18-25 04:30PM
Nov-13-25 02:57PM
08:55AM
08:41AM
Nov-10-25 06:59AM
04:28AM
Nov-05-25 12:35AM
Nov-03-25 04:30PM
Oct-30-25 01:34AM
Oct-29-25 03:47PM
09:30AM
08:05AM
07:23AM
07:06AM
06:58AM
Oct-28-25 09:26AM
Oct-27-25 11:12PM
Oct-20-25 06:44PM
11:36AM
09:34AM
07:41AM
07:25AM
Oct-19-25 08:00PM
Oct-17-25 12:24PM
Oct-10-25 06:44PM
Oct-02-25 11:40AM
Oct-01-25 11:01AM
Sep-25-25 01:06PM
Sep-11-25 07:00AM
Sep-09-25 07:00AM
Sep-08-25 06:56PM
04:30PM
07:00AM
Sep-05-25 12:41AM
Aug-22-25 02:25PM
Aug-20-25 11:31PM
Aug-18-25 05:48PM
05:01PM
Aug-14-25 07:15AM
Aug-12-25 11:55PM
11:48PM
Aug-07-25 12:38AM
Jul-30-25 03:05PM
12:16PM
09:30AM
08:10AM
07:34AM
07:04AM
06:57AM
05:38AM
Jul-29-25 09:27AM
07:00AM
Jul-28-25 11:09PM
Jul-24-25 05:04AM
Jul-23-25 10:00AM
Jul-22-25 08:45AM
Jul-21-25 09:13AM
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bailey A Robert DEVP & Chief Legal OfficerMar 06 '26Buy17.1514,600250,332231,890Mar 10 05:23 PM
Eldessouky SamEVP and CFOMar 06 '26Buy17.134,00068,520403,130Mar 10 04:34 PM
SAUNDERS BRENT LCEO and Chairman of the BoardMar 06 '26Buy17.1414,700251,958966,575Mar 10 04:32 PM
Ross Thomas W. Sr.DirectorMar 03 '26Buy17.684,50079,55664,891Mar 04 04:18 PM
Alfonso EduardoDirectorMar 02 '26Buy17.904,30076,9709,555Mar 03 04:26 PM
VON ESCHENBACH ANDREW C.DirectorFeb 27 '26Buy18.304,36479,88366,450Mar 03 04:24 PM
COLLIS STEVEN HDirectorFeb 23 '26Buy17.8115,000267,15020,255Feb 24 04:23 PM
ROBERTSON RUSSEL CDirectorFeb 20 '26Buy17.904,40078,76072,407Feb 24 04:16 PM
Ling KarenDirectorFeb 19 '26Buy17.744,00070,96841,676Feb 23 04:20 PM
SAUNDERS BRENT LCEO and Chairman of the BoardMay 22 '25Buy11.2822,000248,072719,156May 27 08:16 AM
VON ESCHENBACH ANDREW C.DirectorMay 02 '25Buy11.761,69519,92541,748May 06 04:30 PM